Clinical trials: TNF Alpha
Juvenile Idiopathic Arthritis
A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)
The purpose of this study is to evaluate the efficacy and safety of golimumab (CNTO 148) in patients who have active juvenile idiopathic arthritis (JIA) and at least 5 joints with active arthritis that have poor response to…
- Trial name
- NCT01230827
- Testing
- CNTO 148 (Golimumab), Methotrexate
- Where
- 35 sites in United States, Austria and 10 more
- Volunteers
- 173 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
Clinical Comparative Study to Evaluate the Efficacy and Safety of Recombinant Anti-TNF-alpha Antibodies for Injection
This study compares the similarity of the proportion of subjects who achieved ACR20 at week 30 in the two groups.
- Trial name
- NCT04178850
- Testing
- GB242, Infliximab
- Where
- China
- Volunteers
- 568 people
- Sponsor
- Genor Biopharma Co., Ltd.
Lung Cancer
Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer
This is an open label, Phase 1, dose escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab in patients with immune checkpoint inhibitor refractory non-small cell lung cancer.
- Trial name
- NCT06125197
- Testing
- TILT-123, KEYTRUDA®
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- TILT Biotherapeutics Ltd.
Arthritis, Psoriatic
A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy
The purpose of this study is to evaluate guselkumab efficacy versus placebo in participants with active psoriatic arthritis (PsA) and an inadequate response to Anti-Tumor Necrosis Factor Alpha (TNF-alpha) therapy by assessing the…
- Trial name
- COSMOS (NCT03796858)
- Testing
- Guselkumab 100 mg
- Where
- 117 sites in Belgium, Bulgaria and 12 more
- Volunteers
- 285 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Axial Spondyloarthritis
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis
The purpose of this study is to assess the efficacy of ustekinumab, in adult participants with active radiographic axial spondyloarthritis (AxSpA), who are naive to anti-TNF alpha agents, as measured by the reduction in signs and…
- Trial name
- NCT02437162
- Testing
- Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
- Where
- 57 sites in United States, Czechia and 5 more
- Volunteers
- 347 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease
Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease
CNI-1493-CD05 is an open-label extension study of CNI-1493-CD04. In the CD05 study, patients are eligible for up to 5 courses of semapimod 60 mg IV x 3 days every 6 - 8 weeks.
- Trial name
- CD05 (NCT00740103)
- Testing
- Semapimod
- Where
- 26 sites in United States, Belgium and 3 more
- Volunteers
- 119 people
- Sponsor
- Ferring Pharmaceuticals
Inflammatory Bowel Diseases, Crohn Disease
Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients
The purpose of this observational study is to assess the safety and effectiveness of biosimilar Infliximab in patients with inflammatory bowel disease (IBD) in Saudi Arabia where no visits or intervention(s) additional to the…
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Fistulizing Crohn's Disease, Ulcerative Colitis
- Trial name
- NCT03452501
- Testing
- Infliximab
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 157 people
- Sponsor
- Hikma Pharmaceuticals LLC
Rheumatoid Arthritis
A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)
This 14-week study will observe the gene expression of certain immune cells in patients with rheumatoid arthritis who receive etanercept, infliximab, and adalimumab.
- Trial name
- NCT00724672
- Testing
- etanercept, infliximab, adalimumab
- Sponsor
- Merck Sharp & Dohme LLC
Relapsing Remitting Multiple Sclerosis
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
To determine the efficacy and safety of an oral drug (BGC20-0134) in patients with relapsing remitting multiple sclerosis. Specifically, the cumulative number of new gadolinium enhancing lesions after 24 weeks of treatment with…
- Trial name
- NCT01037907
- Testing
- Pleneva TM BGC20-0134
- Where
- 35 sites in Belgium, France and 4 more
- Volunteers
- 173 people
- Sponsor
- Boston Scientific Corporation
Crohn Disease
A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease
The purpose of this study is to evaluate the efficacy and safety of JNJ-64304500 as add-on therapy to standard of care (SOC) biologic treatment with anti-tumor necrosis factor alpha or anti-interleukin 12/23 inhibitors in…
- Trial name
- DUET (NCT04655807)
- Testing
- JNJ-64304500, Adalimumab, Ustekinumab
- Where
- United States
- Sponsor
- Janssen Research & Development, LLC
Healthy
Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers
This clinical study is a phase 1 study which carried out to establish the pharmacokinetic equivalence and equal safety of human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection and Adalimumab when used…
- Trial name
- NCT02912247
- Testing
- human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, adalimumab
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Crohn's Disease
Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease
The study will continue to assess the safety of certolizumab pegol (CDP870) as well as examine the evolution of long term efficacy in Crohn's disease patients who completed study C87042 [NCT00308581].
- Trial name
- Welcome2 (NCT00333788)
- Testing
- Certolizumab pegol (CDP870)
- Where
- 65 sites in United States, Austria and 10 more
- Volunteers
- 233 people
- Sponsor
- UCB Pharma
Diabetic Nephropathy Type 2
Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial
The goal of this clinical trial is to evaluate the safety and efficacy of a single intra-renal injection of allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) in adults with diabetic nephropathy aged 40 to 65…
- Trial name
- NCT07396155
- Testing
- Umbilical Cord Mesenchymal Stem Cells
- Where
- Indonesia
- Volunteers
- 10 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Ulcerative Colitis
Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC
To evaluate the efficacy and safety of Neihulizumab (ALTB-168) administered intravenously in patients with moderate to severe active ulcerative colitis who are refractory or intolerant to anti-Tumor Necrosis Factor α and/or…
- Trial name
- TNF (NCT03298022)
- Testing
- ALTB-168
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 24 people
- Sponsor
- AltruBio Inc.
Rheumatoid Arthritis
A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy
This study will assess the safety and efficacy of rituximab combined with MTX in participants with active rheumatoid arthritis (RA) who have had an inadequate response to anti-Tumor Necrosis (TNF) alpha therapy.
- Trial name
- NCT00468546
- Testing
- MabThera/Rituxan, Methotrexate
- Where
- 115 sites in United States, Belgium and 9 more
- Volunteers
- 520 people
- Sponsor
- Hoffmann-La Roche
Cancer, Nausea
Efficacy Study of Ginger (Zingiber Officinale) Extract "Ginpax" to Manage Nausea in Cancer Patients Receiving High Emetogenic Treatments and Standard Anti-emetogenic Therapy
The purpose of the study is verify the capability of a standardized Ginger (Zingiber officinale) extract to manage nausea in cancer patients receiving highly emetogenic treatments and standard anti-emetogenic therapy.
- Conditions
- Cancer, Nausea, Vomiting
- Trial name
- NCT01887314
- Testing
- Standardized Ginger extract
- Where
- 6 sites in Italy
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Helsinn Healthcare SA
Osteoarthritis
Study of Intra-articular DLX105 Applied to Patients With Severely Painful Osteoarthritis of the Knee
The purpose of this study is to determine whether an intra-articular injection of DLX105 to the knee joint of patients suffering from severly painful osteoarthritis is safe and reduces pain.
- Trial name
- NCT00819572
- Testing
- DLX105, a single-chain (scFv) antibody fragment against TNF-alpha
- Where
- 10 sites in Germany, Switzerland
- Volunteers
- 27 people
- Sponsor
- ESBATech AG
Rheumatoid Arthritis
Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
The primary objective of this study is to evaluate the efficacy of atacicept compared to placebo in the treatment of signs and symptoms in a subject population with active rheumatoid arthritis (RA), inadequate response to…
- Trial name
- AUGUST II (NCT00595413)
- Testing
- Atacicept: with loading dose, Atacicept, Adalimumab
- Where
- 2 sites in United States, Germany
- Volunteers
- 311 people
- Sponsor
- EMD Serono
Inflammatory Arthritis
Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis
The main purpose of this study is to learn more about the safety of LY3114062 and to find out how well it is tolerated in participants with an inflammatory arthritis.
- Trial name
- NCT02144272
- Testing
- LY3114062 SC, LY3114062 IV
- Where
- 4 sites in Bulgaria, Georgia and 2 more
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company
Arthritis, Psoriatic
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by…
- Trial name
- SOLSTICE (NCT04936308)
- Testing
- Guselkumab
- Where
- 169 sites in United States, Argentina and 12 more
- Volunteers
- 453 people
- Sponsor
- Janssen Research & Development, LLC